Drug Trial Radar · NCT00868166
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
Last checked: Nov 20, 2026Latest source record: Feb 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
512
Actual
Start
Apr 30, 2009
Primary completion
Sep 30, 2011
Study completion Sep 30, 2011
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- European Commission
- First posted
- Mar 24, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month survival rate.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
OlesoximeDrug
2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
Placebo ComparatorDrug
2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
RiluzoleDrug
Riluzole given as add-on therapy 50mg bid
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival Rate at 18 MonthsTime frame: From the date of randomization until the date of death or last follow-up censored at 18 months (548 days)
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49
Leuven, Belgium
HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel
Bron, France
CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement
Lille, France
Centre SLA Limoges - Service de Neurologie
Limoges, France
Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires
Marseille, France
Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac
Montpellier, France
CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA
Nice, France
Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux
Paris, France
Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen
Berlin, Germany
Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg
Halle, Germany
Neurologische Klinik Medizinische Hochschule
Hanover, Germany
Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik
Ulm, Germany
Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10
Madrid, Spain
King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry
London, United Kingdom
Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.